Changing Treatment Landscape of Hepatocellular Carcinoma: A Real-World Retrospective Analysis of Treatment Algorithms and Outcomes of Patients over 10 Years
Targeted Oncology · 2026-09 · 21 (5) · 785-797
DOI: 10.1007/s11523-026-01239-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Targeted Oncology, online erschienen am 26.07.2026. Verfasst von Melanie Bathon und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany. bathon.melanie@mh-hann…. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Medizinische Hochschule Hannover (MHH).
Abstract (Originalsprache)
Background
Hepatocellular carcinoma is one of the most common cancers worldwide and the third leading cause of cancer-related mortality. The therapeutic landscape of hepatocellular carcinoma, especially systemic therapies, is constantly changing and characterized by a multimodal approach.
Objective
The aim of this study was to investigate whether and how treatment sequencing according to tumor stage and liver function has changed over time and if the introduction of new therapeutic options has led to improved survival rates.
Methods
Therapy concepts were retrospectively recorded and evaluated in a cohort of 1288 patients with hepatocellular carcinoma with a first diagnosis between January 2013 and December 2022 who were divided into two cohorts with a cut-off for dividing in 2020 owing to the approval of atezolizumab and bevacizumab for the treatment of hepatocellular carcinoma by the European Medicines Agency (Cohort A initial diagnosis 2013–19, Cohort B initial diagnosis 2020–22). All patients were treated at Hannover Medical School, Germany.
Results
Baseline characteristics differed significantly between cohorts, with Cohort B presenting at earlier tumor stages and with better preserved liver function. Across all treatment modalities, liver function emerged as the primary determinant of prognosis, independent of tumor stage and performance status. Over time, a treatment shift from transarterial chemoembolization towards systemic therapies was observed. Median overall survival from initial diagnosis did not differ between cohorts. In unadjusted analyses, patients treated with immune checkpoint inhibitor-based regimens demonstrated longer median overall survival compared with those receiving tyrosine kinase inhibitors. However, after multivariable adjustment for baseline imbalances, no independent survival difference between treatment groups remained.
Conclusions
This study provides a detailed longitudinal assessment of evolving treatment patterns and outcomes, highlighting a clear shift in therapeutic strategies over time with the increasing adoption of systemic therapies. Despite evolving treatment strategies and increased use of systemic therapies, liver function remained the dominant prognostic factor across treatment settings. Observed survival differences between treatment modalities were strongly influenced by baseline patient characteristics and treatment selection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany. bathon.melanie@mh-hannover.de.
- Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
- Department of Diagnostic and Interventional Radiology, Hannover Medical School, Hannover, Germany.
- Department of General, Visceral and Transplant Surgery, Hannover Medical School, Hannover, Germany.
- Division of Gastroenterology and Hepatology, Toronto General Hospital, Medical Oncology, Princess Margaret Cancer Centre, Schwartz Reisman Liver Research Centre, Toronto, ON, Canada.
Förderung
- Medizinische Hochschule Hannover (MHH)
Zitieren
APA
Bathon, M., Binder, N., Welland, S., Gerdes, C., Wirth, T., Ringe, K. I., Quante, M., Vogel, A., & Saborowski, A. (2026). Changing Treatment Landscape of Hepatocellular Carcinoma: A Real-World Retrospective Analysis of Treatment Algorithms and Outcomes of Patients over 10 Years. Targeted Oncology, 21(5), 785-797. https://doi.org/10.1007/s11523-026-01239-8
Vancouver
Bathon M, Binder N, Welland S, Gerdes C, Wirth T, Ringe KI, et al. Changing Treatment Landscape of Hepatocellular Carcinoma: A Real-World Retrospective Analysis of Treatment Algorithms and Outcomes of Patients over 10 Years. Targeted Oncology. 2026;21(5):785-797. doi:10.1007/s11523-026-01239-8
BibTeX
@article{Bathon2026,
author = {Bathon, Melanie and Binder, Nele and Welland, Sabrina and Gerdes, Christoph and Wirth, Thomas and Ringe, Kristina I and Quante, Markus and Vogel, Arndt and Saborowski, Anna},
title = {Changing Treatment Landscape of Hepatocellular Carcinoma: A Real-World Retrospective Analysis of Treatment Algorithms and Outcomes of Patients over 10 Years},
journal = {Targeted Oncology},
year = {2026},
volume = {21},
number = {5},
pages = {785--797},
doi = {10.1007/s11523-026-01239-8}
}
EUVIMED